Abstract
The microencapsulation of different types of cells that are able to produce therapeutic factors is being investigated for the treatment of several human diseases. Most efforts are focused on chronic and degenerative diseases as this strategy could become an alternative to some commonly used parenteral treatments that need to be repeatedly administered. But, this approach has also been investigated in the field of oncology with the aim of providing immunomodulatory antibodies that are able to enhance the patient’s inherent immune response against the tumor. These kind of treatments would provide the patient with the therapeutic drug produced in situ, de novo, and in a sustained way, making the therapy more comfortable.
Although different devices are nowadays available to produce cell-enclosing alginate-microcapsules, here, we describe the most important steps and advices in order to fabricate alginate-poly-l-lysine-alginate microcapsules containing hybridoma cells for cancer management using an electrostatic bead generator, and how to evaluate the viability of those cells over the time.
Key words
- Cell microencapsulation
- Electrostatic bead generator
- Alginate
- Hybridoma cells
- Controlled drug delivery system
- Microtechnology
- Cancer
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Orive G, Santos E, Pedraz JL, Hernandez RM (2014) Application of cell encapsulation for controlled delivery of biological therapeutics. Adv Drug Deliv Rev 67–68:3–14
de Vos P, Lazarjani HA, Poncelet D, Faas MM (2014) Polymers in cell encapsulation from an enveloped cell perspective. Adv Drug Deliv Rev 67–68:15–34
de Vos P, Faas MM, Strand B, Calafiore R (2006) Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials 27(32):5603–5617
Lee KY, Mooney DJ (2012) Alginate: properties and biomedical applications. Prog Polym Sci 37(1):106–126
Gasperini L, Mano JF, Reis RL (2014) Natural polymers for the microencapsulation of cells. J R Soc Interface 11(100):20140817
Orive G, Ponce S, Hernandez RM, Gascon AR, Igartua M, Pedraz JL (2002) Biocompatibility of microcapsules for cell immobilization elaborated with different type of alginates. Biomaterials 23(18):3825–3831
De Castro M, Orive G, Hernandez RM, Gascon AR, Pedraz JL (2005) Comparative study of microcapsules elaborated with three polycations (PLL, PDL, PLO) for cell immobilization. J Microencapsul 22(3):303–315
Acarregui A, Murua A, Pedraz JL, Orive G, Hernandez RM (2012) A perspective on bioactive cell microencapsulation. BioDrugs 26(5):283–301
Calafiore R, Basta G (2014) Clinical application of microencapsulated islets: actual prospectives on progress and challenges. Adv Drug Deliv Rev 67–68:84–92
Basta G, Montanucci P, Luca G, Boselli C, Noya G, Barbaro B et al (2011) Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts: four cases. Diabetes Care 34(11):2406–2409
Ferreira D, Westman E, Eyjolfsdottir H, Almqvist P, Lind G, Linderoth B et al (2015) Brain changes in Alzheimer’s disease patients with implanted encapsulated cells releasing nerve growth factor. J Alzheimers Dis 43(3):1059–1072
Bachoud-Levi AC, Deglon N, Nguyen JP, Bloch J, Bourdet C, Winkel L et al (2000) Neuroprotective gene therapy for Huntington’s disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 11(12):1723–1729
Zurn AD, Henry H, Schluep M, Aubert V, Winkel L, Eilers B et al (2000) Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells. Cell Transplant 9(4):471–484
Emerich DF, Orive G, Thanos C, Tornoe J, Wahlberg LU (2014) Encapsulated cell therapy for neurodegenerative diseases: from promise to product. Adv Drug Deliv Rev 67–68:131–141
Saenz Del Burgo L, Compte M, Aceves M, Hernandez RM, Sanz L, Alvarez-Vallina L et al (2015) Microencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer management. J Drug Target 23(2):170–179
Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10(5):345–352
Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L (2007) Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7(2):95–106
Compte M, Blanco B, Serrano F, Cuesta AM, Sanz L, Bernad A et al (2007) Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 14(4):380–388
Kontermann R (2012) Dual targeting strategies with bispecific antibodies. MAbs 4(2):182–197
Dubrot J, Portero A, Orive G, Hernandez RM, Palazon A, Rouzaut A et al (2010) Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. Cancer Immunol Immunother 59(11):1621–1631
Murillo O, Arina A, Tirapu I, Alfaro C, Mazzolini G, Palencia B et al (2003) Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin Cancer Res 9(15):5454–5464
Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297–339
Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA et al (2007) Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25(7):876–883
Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018–1028
Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS et al (2006) Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 12(6):693–698
Manojlovic V, Djonlagic J, Obradovic B, Nedovic V, Bugarski B (2006) Immobilization of cells by electrostatic droplet generation: a model system for potential application in medicine. Int J Nanomedicine 1(2):163–171
Bugarski B, Li QL, Goosen MFA, Poncelet D, Neufeld RJ et al (1994) Electrostatic droplet generation – mechanism of polymer droplet formation. Aiche J 40(6):1026–1031
Poncelet D, Babak VG, Neufeld RJ, Goosen MFA, Burgarski B (1999) Theory of electrostatic dispersion of polymer solutions in the production of microgel beads containing biocatalyst. Adv Colloid Interf Sci 79(2-3):213–228
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Saenz del Burgo, L., Ciriza, J., Hernández, R.M., Orive, G., Pedraz, J.L. (2017). Microencapsulated Cells for Cancer Therapy. In: Opara, E. (eds) Cell Microencapsulation. Methods in Molecular Biology, vol 1479. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6364-5_21
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6364-5_21
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6362-1
Online ISBN: 978-1-4939-6364-5
eBook Packages: Springer Protocols